Healthcare
HeartBeam (BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study
LOS ANGELES, CA - June 30, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) announced it has completed patient enrollment ahead of schedule in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study enrolled 120 ...
About this update from Heartbeam, Inc.
LOS ANGELES, CA - June 30, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) announced it has completed patient enrollment ahead of schedule in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study enrolled 120 patients presenting with chest pain at two clinical sites in Belgrade, Serbia, with participants evaluated using both a standard 12-lead ECG and the company's 3D ECG technology. Data analysis is underway, and HeartBeam plans to present the results at a major cardiology conference later this year. The company said the study results are expected to support discussions with the FDA on the design of a planned U.S. pivotal trial and a future submission to expand the HeartBeam System's indication beyond arrhythmia assessment to include heart attack detection. HeartBeam is also evaluating whether completing enrollment ahead of its previously anticipated third-quarter 2026 timeline could support a more accelerated regulatory pathway. To view the full press release, visit https://ibn.fm/GEYtp About HeartBeam, Inc. HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement. (1)Cleared Indications for Use The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company's Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, w...